{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T20:40:47Z","timestamp":1770237647498,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12026-025-09691-w","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T03:32:59Z","timestamp":1758252779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The double-edged sword of PI3K\u03b4 pathway-related immune dysregulation: insights from two case reports"],"prefix":"10.1007","volume":"73","author":[{"given":"Marta Dafne","family":"Cabanero-Navalon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Garcia-Bustos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santos","family":"Ibanez-Barcelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9ctor","family":"Balastegui-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Grimaldos-Lodares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Moral-Moral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"issue":"6160","key":"9691_CR1","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1126\/science.1243292","volume":"342","author":"I Angulo","year":"2013","unstructured":"Angulo I, Vadas O, Gar\u00e7on F, Banham-Hall E, Plagnol V, Leahy TR, et al. Phosphoinositide 3-kinase \u03b4 gene mutation predisposes to respiratory infection and airway damage. Science. 2013;342(6160):866\u201371. https:\/\/doi.org\/10.1126\/science.1243292.","journal-title":"Science"},{"key":"9691_CR2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.coi.2021.04.010","volume":"72","author":"NN Brodsky","year":"2021","unstructured":"Brodsky NN, Lucas CL. Infections in activated PI3K delta syndrome (APDS). Curr Opin Immunol. 2021;72:146\u201357. https:\/\/doi.org\/10.1016\/j.coi.2021.04.010.","journal-title":"Curr Opin Immunol"},{"key":"9691_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1033666","volume":"13","author":"MD Caba\u00f1ero-Navalon","year":"2022","unstructured":"Caba\u00f1ero-Navalon MD, Garcia-Bustos V, Nu\u00f1ez-Beltran M, C\u00edscar Fern\u00e1ndez P, Mateu L, Solanich X, et al. Current clinical spectrum of common variable immunodeficiency in Spain: the multicentric nationwide GTEM-SEMI-CVID registry. Front Immunol. 2022;13: 1033666. https:\/\/doi.org\/10.3389\/fimmu.2022.1033666.","journal-title":"Front Immunol"},{"issue":"1","key":"9691_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jaip.2023.09.016","volume":"12","author":"AJ Cant","year":"2024","unstructured":"Cant AJ, Chandra A, Munro E, Rao VK, Lucas CL. PI3K\u03b4 pathway dysregulation and unique features of its inhibition by leniolisib in activated PI3K\u03b4 syndrome and beyond. J Allergy Clin Immunol Pract. 2024;12(1):69\u201378. https:\/\/doi.org\/10.1016\/j.jaip.2023.09.016.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"9691_CR5","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.4049\/jimmunol.1701703","volume":"202","author":"S Chellappa","year":"2019","unstructured":"Chellappa S, Kushekhar K, Munthe LA, Tj\u00f8nnfjord GE, Aandahl EM, Okkenhaug K, et al. The PI3K p110\u03b4 isoform inhibitor idelalisib preferentially inhibits human regulatory T cell function. J Immunol. 2019;202(5):1397\u2013405. https:\/\/doi.org\/10.4049\/jimmunol.1701703.","journal-title":"J Immunol"},{"key":"9691_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00338","volume":"9","author":"AM Condliffe","year":"2018","unstructured":"Condliffe AM, Chandra A. Respiratory manifestations of the activated phosphoinositide 3-kinase delta syndrome. Front Immunol. 2018;9: 338. https:\/\/doi.org\/10.3389\/fimmu.2018.00338.","journal-title":"Front Immunol"},{"issue":"9","key":"9691_CR7","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1172\/JCI75746","volume":"124","author":"MC Deau","year":"2014","unstructured":"Deau MC, Heurtier L, Frange P, Suarez F, Bole-Feysot C, Nitschke P, et al. A human immunodeficiency caused by mutations in the PIK3R1 gene. J Clin Invest. 2014;124(9):3923\u20138. https:\/\/doi.org\/10.1172\/JCI75746.","journal-title":"J Clin Invest"},{"issue":"9","key":"9691_CR8","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1182\/blood.2019002072","volume":"135","author":"A Durandy","year":"2020","unstructured":"Durandy A, Kracker S. Increased activation of PI3 kinase-\u03b4 predisposes to B-cell lymphoma. Blood. 2020;135(9):638\u201343. https:\/\/doi.org\/10.1182\/blood.2019002072.","journal-title":"Blood"},{"key":"9691_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13223-020-00420-6","volume":"16","author":"M Ewertowska","year":"2020","unstructured":"Ewertowska M, Grze\u015bk E, Urba\u0144czyk A, D\u0105browska A, B\u0105bol-Pokora K, \u0141\u0119cka M, et al. Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS 1 and APDS 2): similarities and differences based on clinical presentation in two boys. Allergy Asthma Clin Immunol. 2020;16:22. https:\/\/doi.org\/10.1186\/s13223-020-00420-6.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"9691_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s12016-019-08738-9","volume":"59","author":"M Jamee","year":"2020","unstructured":"Jamee M, Moniri S, Zaki-Dizaji M, Olbrich P, Yazdani R, Jadidi-Niaragh F, et al. Clinical, immunological, and genetic features in patients with activated PI3K\u03b4 syndrome (APDS): a systematic review. Clin Rev Allergy Immunol. 2020;59(3):323\u201333. https:\/\/doi.org\/10.1007\/s12016-019-08738-9.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"9691_CR11","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri.2016.93","volume":"16","author":"CL Lucas","year":"2016","unstructured":"Lucas CL, Chandra A, Nejentsev S, Condliffe AM, Okkenhaug K. PI3K\u03b4 and primary immunodeficiencies. Nat Rev Immunol. 2016;16(11):702\u201314. https:\/\/doi.org\/10.1038\/nri.2016.93.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"9691_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/ni.2771","volume":"15","author":"CL Lucas","year":"2014","unstructured":"Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110\u03b4 result in T cell senescence and human immunodeficiency. Nat Immunol. 2014;15(1):88\u201397. https:\/\/doi.org\/10.1038\/ni.2771.","journal-title":"Nat Immunol"},{"issue":"5","key":"9691_CR13","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.jaci.2019.03.017","volume":"143","author":"CJ Nunes-Santos","year":"2019","unstructured":"Nunes-Santos CJ, Uzel G, Rosenzweig SD. PI3K pathway defects leading to immunodeficiency and immune dysregulation. J Allergy Clin Immunol. 2019;143(5):1676\u201387. https:\/\/doi.org\/10.1016\/j.jaci.2019.03.017.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"9691_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nri1056","volume":"3","author":"K Okkenhaug","year":"2003","unstructured":"Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003;3(4):317\u201330. https:\/\/doi.org\/10.1038\/nri1056.","journal-title":"Nat Rev Immunol"},{"key":"9691_CR15","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1146\/annurev-immunol-032712-095946","volume":"31","author":"K Okkenhaug","year":"2013","unstructured":"Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol. 2013;31:675\u2013704. https:\/\/doi.org\/10.1146\/annurev-immunol-032712-095946.","journal-title":"Annu Rev Immunol"},{"key":"9691_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.702872","volume":"9","author":"V Redenbaugh","year":"2021","unstructured":"Redenbaugh V, Coulter T. Disorders related to PI3K\u03b4 hyperactivation: characterizing the clinical and immunological features of activated PI3-kinase delta syndromes. Front Pediatr. 2021;9: 702872. https:\/\/doi.org\/10.3389\/fped.2021.702872.","journal-title":"Front Pediatr"},{"key":"9691_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/bs.ai.2020.02.001","volume":"146","author":"G Sogkas","year":"2020","unstructured":"Sogkas G, Adriawan IR, Dubrowinskaja N, Atschekzei F, Schmidt RE. Homeostatic and pathogenic roles of PI3K\u03b4 in the human immune system. Adv Immunol. 2020;146:109\u201337. https:\/\/doi.org\/10.1016\/bs.ai.2020.02.001.","journal-title":"Adv Immunol"},{"issue":"6","key":"9691_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129658","volume":"10","author":"O Traitanon","year":"2015","unstructured":"Traitanon O, Mathew JM, La Monica G, Xu L, Mas V, Gallon L. Differential effects of tacrolimus versus sirolimus on the proliferation, activation and differentiation of human B cells. PLoS ONE. 2015;10(6): e0129658. https:\/\/doi.org\/10.1371\/journal.pone.0129658.","journal-title":"PLoS ONE"},{"key":"9691_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1208567","volume":"14","author":"S Vanselow","year":"2023","unstructured":"Vanselow S, Wahn V, Schuetz C. Activated PI3K\u03b4 syndrome - reviewing challenges in diagnosis and treatment. Front Immunol. 2023;14: 1208567. https:\/\/doi.org\/10.3389\/fimmu.2023.1208567.","journal-title":"Front Immunol"},{"issue":"6016","key":"9691_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/315239a0","volume":"315","author":"M Whitman","year":"1985","unstructured":"Whitman M, Kaplan DR, Schaffhausen B, Cantley L, Roberts TM. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature. 1985;315(6016):239\u201342. https:\/\/doi.org\/10.1038\/315239a0.","journal-title":"Nature"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-025-09691-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-025-09691-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-025-09691-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:30:48Z","timestamp":1770190248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-025-09691-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9691"],"URL":"https:\/\/doi.org\/10.1007\/s12026-025-09691-w","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Both patients have consented to the submission of the case reports to the journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was obtained from both individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The publication fees and medical writing services for this article have been covered by Pharming Group. However, Pharming has not been directly involved in the design or drafting of the publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"132"}}